Study to investigate safety, tolerability and pharmacokinetics of AZD2423 in healthy volunteers - SAD

Study identifier:D2600C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, tolerability and Pharmacokinetics of oral AZD2423 after Single Ascending Doses in Healthy Male and Female Volunteers without Childbearing Potential

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2423, Placebo

Sex

All

Actual Enrollment

80

Study type

Interventional

Age

20 Years - 55 Years

Date

Study Start Date: 01 Jul 2009
Primary Completion Date: 01 Nov 2009
Study Completion Date: 01 Nov 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria